Comparison
BPC-157 vs N-Acetyl Cysteine
Side-by-side of BPC-157 and N-Acetyl Cysteine. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
N-Acetyl Cysteine
NAC supplement benefits cover glutathione synthesis, liver and antioxidant support, and hangover recovery. Evidence strongest at 1200-2400 mg/day.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
N-Acetyl Cysteine
- •Replenishes intracellular glutathione by supplying cysteine, the rate-limiting amino acid for synthesis
- •First-line antidote for acetaminophen toxicity, restoring hepatic glutathione before fulminant injury occurs
- •Reduces sputum viscosity in chronic bronchitis and COPD at 600 to 1200 mg/day over months
- •Modest symptom reductions in OCD and trichotillomania at 1200 to 2400 mg/day across small RCTs
- •Mixed evidence for psychiatric adjunct use in bipolar depression and schizophrenia negative symptoms
- •Inhaled forms can trigger bronchospasm in active asthma; oral use is the standard biohacker route
Side-by-side
| Attribute | BPC-157 | N-Acetyl Cysteine |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | NAC |
| Half-life (hr) ↗ | 4 | 5.6 |
| Typical dose (mg) ↗ | 0.25 | 1200 |
| Dosing frequency | daily (anecdotal protocols) | 1 to 3 times daily, split dosing preferred |
| Routes | subcutaneous, intramuscular, oral | oral, iv |
| Onset (hr) | - | 1 |
| Peak (hr) | - | 2 |
| Molecular weight | - | 163.19 |
| Molecular formula | C62H98N16O22 | C5H9NO3S |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Deacetylated to cysteine, the rate-limiting precursor for glutathione synthesis; also directly scavenges reactive oxygen species and modulates glutamate signaling. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | OTC in most jurisdictions; restricted periods in US history (FDA reclassified 2022) |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | OTC supplement (US, post-2022); Rx indications also exist (acetaminophen overdose, mucolytic) |
| Pregnancy | Insufficient data | Used clinically in pregnancy for specific indications; consult clinician |
| CAS | 137525-51-0 | 616-91-1 |
| PubChem CID | 9941957 | 12035 |
| Wikidata | Q4835418 | Q413299 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
N-Acetyl Cysteine
Common side effects
- sulfur-like taste or odor
- nausea
- flatulence
- diarrhea
Contraindications
- active asthma attack (inhaled form can trigger bronchospasm)
- known NAC hypersensitivity
Interactions
- nitroglycerin: potentiates vasodilation, risk of hypotension and headache(moderate)
- activated charcoal: reduces NAC absorption when used for acetaminophen overdose(moderate)
- anticoagulants: theoretical additive antiplatelet effect at high doses(minor)
Which Should You Take?
N-Acetyl Cysteine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC, oral dosing, with a Tier-A outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is healthspan extension, pick N-Acetyl Cysteine.
- → If your priority is liver function, pick N-Acetyl Cysteine.
Edge case: If you want to avoid research-only / gray-market sourcing, N-Acetyl Cysteine is the more accessible choice.
Default choice: N-Acetyl Cysteine. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and N-Acetyl Cysteine?
BPC-157 and N-Acetyl Cysteine differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or N-Acetyl Cysteine?
BPC-157 half-life is 4 hours; N-Acetyl Cysteine half-life is 5.6 hours.
Can you stack BPC-157 with N-Acetyl Cysteine?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper